Phenotype of a modern patient with valvular heart diseases: literature review

Cover Page

Cite item

Full Text

Abstract

In modern conditions, valvular heart diseases (VHD) are one of the most common pathologies among cardiovascular diseases with a dynamic change in the phenotype of patients. An increase in the prevalence of VHD is currently observed due to the active implementation of diagnostic methods in cardiology. Geographical differences in the genesis of the development of valvular heart defects are noted, and the portrait of patients also changes as a result of aging and the addition of comorbid pathology. The purpose of the literature review was to present current trends in changing phenotype of patients with VHD, to study current data on the epidemiology of valve pathology, the contribution of various cardiovascular risk factors and comorbidity of patients on the course of the disease. Current data on the number of surgical interventions performed for VHD based on Russian, European, American, Australian and other studies, data on patient survival and mortality, as well as differences in these indicators in age groups of different countries are presented. The review will be useful for doctors to understand the modern portrait of a patient with VHD, trends in cardiovascular risk factors that influence the course of the disease and prognosis in patients with VHD.

About the authors

Elena V. Dren'

Research Institute for Complex Issues of Cardiovascular Diseases

Author for correspondence.
Email: e.tolpekina.v@mail.ru
ORCID iD: 0000-0002-5469-7638
SPIN-code: 7469-2856

graduate student, laboratory researcher

Russian Federation, Kemerovo

irina N. Lyapina

Research Institute for Complex Issues of Cardiovascular Diseases

Email: zaviirina@mail.ru
ORCID iD: 0000-0002-4649-5921
SPIN-code: 4741-6753

MD, Cand. Sci. (Med.), senior researcher

Russian Federation, Kemerovo

Tamara B. Pecherina

Research Institute for Complex Issues of Cardiovascular Diseases

Email: tb.pechorina@gmail.com
ORCID iD: 0000-0002-4771-484X
SPIN-code: 6780-9141

MD, Dr. Sci. (Med.), laboratory head

Russian Federation, Kemerovo

Olga L. Barbarash

Research Institute for Complex Issues of Cardiovascular Diseases

Email: barbol@kemcardio.ru
ORCID iD: 0000-0002-4642-3610
SPIN-code: 5373-7620

MD, Dr. Sci. (Med.), Professor, Academician of RAS, head of institution

Russian Federation, Kemerovo

References

  1. Shlyakhto EV, editor. Cardiology. National Guide. 2nd edition, revised and expanded. Moscow: GEOTAR-Media; 2019. (In Russ).
  2. Santangelo G, Bursi F, Faggiano A, et al. The Global Burden of Valvular Heart Disease: From Clinical Epidemiology to Management. J Clin Med. 2023;12(6):2178. doi: 10.3390/jcm12062178
  3. Sharma T, Krishnan AM, Lahoud R, et al. National Trends in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis. J Am Coll Cardiol. 2022;80(21):2054–2056. doi: 10.1016/j.jacc.2022.08.787
  4. Golukhova EZ. Report on the scientific and clinical activity of the Bakoulev National Medical Research Center for Cardiovascular Surgery for 2021 and development prospects. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2022;23(S):5–111. (In Russ). doi: 10.24022/1810-0694-2022-23S
  5. van der Heijden CAJ, Verheule S, Olsthoorn J, et al. Postoperative atrial fibrillation and atrial epicardial fat: Is there a link? Int J Cardiol Heart Vasc. 2022;(39):100976. doi: 10.1016/j.ijcha.2022.100976
  6. Deeva NS, Shabaldin AV, Antonova LV. The role of calcium metabolism disorders in induction of hypersensitivity in cardiovascular diseases. Bulletin of Siberian Medicine. 2021;20(3):141–151. (In Russ). doi: 10.20538/1682-0363-2021-3-141-151
  7. Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. 2021;128(7):951–968. doi: 10.1161/CIRCRESAHA.121.318093
  8. Iung B, Delgado V, Rosenhek R, et al. Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation. 2019;140(14):1156–1169. doi: 10.1161/CIRCULATIONAHA.119.041080
  9. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292. doi: 10.1161/01.cir.0000441139.02102.80
  10. Aluru JS, Barsouk A, Saginala K, et al. Valvular Heart Disease Epidemiology. Med Sci (Basel). 2022;10(2):32. doi: 10.3390/medsci10020032
  11. Shlyakhto EV, editor. Cardiology. National Guide. 2nd edition, revised and expanded. Moscow: GEOTAR-Media; 2015. (In Russ).
  12. Georgikia RK, Kharitonov GI. Modern aspects of diagnosis and surgical treatment of acquired heart defects. Prakticheskaya meditsina. 2003;(2):25–26. (In Russ).
  13. Rubanenko AO, D'yachkov VA, Shchukin YuV, et al. Аcquired valvular heart diseases: clinical picture and diagnostics. Cardiology: News, Opinions, Training. 2019;7(3):26–36. (In Russ). doi: 10.24411/2309-1908-2019-13003
  14. Order of the Ministry of Health of the Russian Federation No. 283 of 30 November 1993 «O sovershenstvovanii sluzhby funktsional'noi diagnostiki v uchrezhdeniyakh zdravookhraneniya Rossiiskoi Federatsii». Available from: https://normativ.kontur.ru/document?moduleId=1&documentId=71530. Accessed: 10.11.2023. (In Russ).
  15. Tyurin IE. Radiology in the Russian Federation in 2016. Journal of radiology and nuclear medicine. 2017;98(4):219–226. (In Russ). doi: 10.20862/0042-4676-2017-98-4-219-226
  16. Sachek OI, Beresten' NF, Tolmachev DA, Oskov YuI. Provision and staffing of outpatient clinics by doctors of functional diagnostics in the Russian Federation, federal districts and pilot subjects in 2012–2016. Medical Alphabet. 2018;1(14):7–12. (In Russ).
  17. Beckmann A, Funkat AK, Lewandowski J, et al. German heart surgery report 2015: the annual updated registry of the German society for thoracic and cardiovascular surgery. Thorac Cardiovasc Surg. 2016;64(6):462–474. doi: 10.1055/s-0036-1592124
  18. Khubulava GG, Gulyaev NI, Kravchuk VN, et al. Incidence of degenerative aortic stenosis in the patterns of valvular heart disease. Russian Journal of Thoracic and Cardiovascular Surgery. 2018;60(1):28–35. (In Russ). doi: 10.24022/0236-2791-2018-60-1-28-35
  19. Semenov VYu, Samorodskaya IV, Larina VN, Andreev EM. Mortality from acquired heart disease during a 15 year period in the Russian Federation and the United States and an analysis of the factors influencing their formation. Kreativnaya kardiologiya. 2017;11(3):235–246. (In Russ). doi: 10.24022/1997-3187-2017-11-2-235-246
  20. Yadgir S, Johnson CO, Aboyans V, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990–2017. Circulation. 2020;141(21):1670–1680. doi: 10.1161/CIRCULATIONAHA.119.043391
  21. Shariff M, Kumar A, Hirji SA, et al. Ten Years Mortality Trends of Tricuspid Regurgitation in the United States, 2008 to 2018. Am J Cardiol. 2021;(140):156–157. doi: 10.1016/j.amjcard.2020.11.024
  22. Pierard S, Seldrum S, de Meester C, et al. Incidence, determinants, and prognostic impact of operative refusal or denial in octogenarians with severe aortic stenosis. Ann Thorac Surg. 2011;91(4):1107–1112. doi: 10.1016/j.athoracsur.2010.12.052
  23. Huang X, Dhruva SS, Yuan X, et al. Characteristics, interventions and outcomes of patients with valvular heart disease hospitalised in China: a cross-sectional study. BMJ Open. 2021;11(11):e052946. doi: 10.1136/bmjopen-2021-052946
  24. Izumi C, Matsuyama R, Yamabe K, et al. In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data. Clinicoecon Outcomes Res. 2023;(15):349–360. doi: 10.2147/CEOR.S405079
  25. Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371(23):2178–2188. doi: 10.1056/NEJMoa1410490
  26. Virk SA, Sriravindrarajah A, Dunn D, et al. A meta-analysis of mitral valve repair versus replacement for ischemic mitral regurgitation. Ann Cardiothorac Surg. 2015;4(5):400–410. doi: 10.3978/j.issn.2225-319X.2015.09.06
  27. Sabate M, Canovas S, Garcia E, et al. In-hospital and mid-term predictors of mortality after transcatheter aortic valve implantation: data from the TAVI National Registry 2010–2011. Rev Esp Cardiol (Engl Ed). 2013;66(12):949–958. doi: 10.1016/j.rec.2013.07.003
  28. Rodés-Cabau J, Dumont E, De LaRochellière R, et al. Feasibility and initial results of percutaneous aortic valve implantation including selection of the transfemoral or transapical approach in patients with severe aortic stenosis. Am J Cardiol. 2008;102(9):1240–1246. doi: 10.1016/j.amjcard.2008.06.061
  29. Dreyfus J, Audureau E, Bohbot Y, et al. TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J. 2022;43(7):654–662. doi: 10.1093/eurheartj/ehab679
  30. Coffey S, Harper AR, Cairns BJ, et al. Clinical information has low sensitivity for postmortem diagnosis of heart valve disease. Heart. 2017;103(13):1031–1035. doi: 10.1136/heartjnl-2016-310718
  31. Marangou J, Beaton A, Aliku TO, et al. Echocardiography in Indigenous Populations and Resource Poor Settings. Heart Lung Circ. 2019;28(9):1427–1435. doi: 10.1016/j.hlc.2019.05.176
  32. Kang D, Bach DS, Chetcuti S, et al. Mortality Predictors in Patients Referred for but Not Undergoing Transcatheter Aortic Valve Replacement. Am J Cardiol. 2015;116(6):919–924. doi: 10.1016/j.amjcard.2015.06.014
  33. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26(24):2714–2720. doi: 10.1093/eurheartj/ehi471
  34. Zhang H, El-Am EA, Thaden JJ, et al. Atrial fibrillation is not an independent predictor of outcome in patients with aortic stenosis. Heart. 2020;106(4):280–286. doi: 10.1136/heartjnl-2019-314996
  35. Ancona R, Pinto SC. Epidemiology of aortic valve stenosis (AS) and of aortic valve incompetence (AI): is the prevalence of AS/AI similar in different parts of the world? e-Journal of Cardiology Practice. 2020;(18):10. Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-18/epidemiology-of-aortic-valve-stenosis-as-and-of-aortic-valve-incompetence-ai. Accessed: 10.11.2023.
  36. Bockeria LA, Amiragov RA, Asatryan TV, et al. Aortic stenosis. Clinical recommendations. Moscow: Minzdrav Rossii; 2020. (In Russ).
  37. d'Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37(47):3515–3522. doi: 10.1093/eurheartj/ehw229
  38. Shu C, Chen S, Qin T, et al. Prevalence and correlates of valvular heart diseases in the elderly population in Hubei, China. Sci Rep. 2016;(6):27253. doi: 10.1038/srep27253
  39. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology / American Heart Association task force on practice guidelines. Circulation. 2014;129(23):2440–2492. doi: 10.1161/CIR.0000000000000029. Erratum in: Circulation. 2014;129(23):e650.
  40. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology / American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021;143(5):e72–e227. doi: 10.1161/CIR.0000000000000923. Erratum in: Circulation. 2021;143(5):e229. Erratum in: Circulation. 2023;148(8):e8.
  41. Bustamante-Munguira J, Centella T, Polo L, Hornero F. Cardiovascular surgery in Spain during 2014. The registry of the Spanish Society of Thoracic-Cardiovascular Surgery. Cirugía Cardiovascular. 2015;22(6):297–313. (In Spanish). doi: 10.1016/j.circv.2015.09.008
  42. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231–1243. doi: 10.1016/s0195-668x(03)00201-x
  43. Banovic M, DaCosta M. Degenerative Mitral Stenosis: From Pathophysiology to Challenging Interventional Treatment. Curr Probl Cardiol. 2019;44(1):10–35. doi: 10.1016/j.cpcardiol.2018.03.004
  44. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019;74(20):2529–2532. doi: 10.1016/j.jacc.2019.10.009
  45. Prihadi EA, van der Bijl P, Gursoy E, et al. Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. Eur Heart J. 2018;39(39):3574–3581. doi: 10.1093/eurheartj/ehy352
  46. Komlev AE, Saidova MA, Imaev TE, Akchurin RS. Diagnosis and transcatheter treatment of tricuspid regurgitation. Russian Cardiology Bulletin. 2022;17(2):5–15. (In Russ). doi: 10.17116/Cardiobulletin2022170215
  47. Riesenhuber M, Spannbauer A, Gwechenberger M, et al. Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation. Clin Res Cardiol. 2021;110(6):884–894. doi: 10.1007/s00392-021-01812-3
  48. Vasques F, Lucenteforte E, Paone R, et al. Outcome of patients aged ≥80 years undergoing combined aortic valve replacement and coronary artery bypass grafting: a systematic review and meta-analysis of 40 studies. Am Heart J. 2012;164(3):410.e1–418.e1. doi: 10.1016/j.ahj.2012.06.019
  49. Brown JM, O'Brien SM, Wu C, et al. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg. 2009;137(1):82–90. doi: 10.1016/j.jtcvs.2008.08.015
  50. Bonnet V, Boisselier C, Saplacan V, et al. The role of age and comorbidities in postoperative outcome of mitral valve repair: A propensity-matched study. Medicine (Baltimore). 2016;95(25):e3938. doi: 10.1097/MD.0000000000003938
  51. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. doi: 10.1016/S0140-6736(14)61682-2
  52. Barbarash OL, Odarenko YuN, Kondyukova NV. Quality of life indicators in evaluating the efficiency of surgical treatment in patients with acquired heart diseases undergoing bioprosthetic and mechanical heart valve replacement. Kreativnaya kardiologiya. 2019;3(1):28–39. (In Russ). doi: 10.24022/1997-3187-2019-13-1-28-39
  53. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. N Engl J Med. 2017;377(8):713–722. doi: 10.1056/NEJMoa1603693
  54. Arora S, Ramm CJ, Bahekar AA, Vavalle JP. Evaluating Health of Emerging Economies Through the Eyes of Heart Valve Disease in the Transcatheter Era. Glob Heart. 2017;12(4):301–304. doi: 10.1016/j.gheart.2017.01.016
  55. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral Annulus Calcification. J Am Coll Cardiol. 2015;66(17):1934–1941. doi: 10.1016/j.jacc.2015.08.872
  56. Sazonenkov MA, Ismatov HH, Ernst EE, et al. Operated mitral valve disease. The structure of the etiology and types of surgical intervention for the period 2015–2020 in the cardiac surgery department of Belgorod Regional Clinical Hospital. Challenges in modern medicine. 2020;43(4):590–602. (In Russ). doi: 10.18413/2687-0940-2020-43-4-590-602
  57. Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222–3232. doi: 10.1093/eurheartj/ehz620. Erratum in: Eur Heart J. 2020;41(22):2091.
  58. DesJardin JT, Chikwe J, Hahn RT, et al. Sex Differences and Similarities in Valvular Heart Disease. Circ Res. 2022;130(4):455–473. doi: 10.1161/CIRCRESAHA.121.319914
  59. Bockeria LA, Klimchuk IYa. Mitral regurgitation in patients with atrial fibrillation. Current state of the problem, approaches to diagnosis and complex surgical treatment. Annaly aritmologii. 2015;12(4):201–214. (In Russ). doi: 10.15275/annaritmol.2015.4.2
  60. Evtushenko VV, Makogonchuk IS, Evtushenko AV. Rules and principles of patient selection for surgical treatment of acquired heart diseases complicated by atrial fibrillation. The Siberian Journal of Clinical and Experimental Medicine. 2017;32(3):29–34. (In Russ). doi: 10.29001/2073-8552-2017-32-3-29-34
  61. Semenova EI, Zheleznev SI, Semenov II, et al. Cardiac valves’ prosthetics in elderly patients. Risk factors: associated morbidity. The Siberian Journal of Clinical and Experimental Medicine. 2007;22(3):97–100. (In Russ).
  62. Charalampopoulos A, Lewis R, Hickey P, et al. Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease. Front Med (Lausanne). 2018;(5):174. doi: 10.3389/fmed.2018.00174
  63. Nikishchenkova YuV, Nikiforov VS, Zheltysheva ZhA, et al. Acquired heart defects in elderly and senile patients. Current issues of clinical practice, diagnosis and treatment of diseases among veterans of the Great Patriotic War in a multidisciplinary hospital. Collection of scientific papers. Vol. 7. Kabanov MYu, editor. St. Petersburg: RGPU im. A.I. Gertsena; 2015. P. 136–141. (In Russ).
  64. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619. doi: 10.1093/eurheartj/ehu278
  65. Petrov VS. Prevalence of endothelial dysfunction and dyslipidemia in patients with chronic rheumatic heart disease. Meditsinskiy sovet = Medical Council. 2019;(12):14–18. (In Russ). doi: 10.21518/2079-701X-2019-12-14-18
  66. Emren ZY, Emren SV, Kılıçaslan B, et al. Evaluation of the prevalence of coronary artery disease in patients with valvular heart disease. J Cardiothorac Surg. 2014;(9):153. doi: 10.1186/s13019-014-0153-1
  67. Karas'kov AM, Zheleznev SI, Semenova EI, et al. Arterial hypertension as a risk factor in surgical treatment of acquired heart defects in patients over 60 years of age. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2007;(2):3–6. (In Russ).
  68. Skopin II, Otarov AM. Preoperative risk factors in elderly patients undergoing aortic valve replacement. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2017;18(3):243–255. (In Russ). doi: 10.24022/1810-0694-2017-18-3-243-25
  69. Barakhovskaya TV, Suvorova EA, Popova ES, Kalyagin AN. The comparative analysis of the course, outputs and the features of treatment of degenerative and rheumatic heart diseases. Siberian Medical Journal (Irkutsk). 2017;150(3):19–22. (In Russ).
  70. Akiyoshi T, Ota H, Iijima K, et al. A novel organ culture model of aorta for vascular calcification. Atherosclerosis. 2016;(244):51–58. doi: 10.1016/j.atherosclerosis.2015.11.005
  71. Guler S, Varol E. The relation between echocardiographic epicardial fat thickness and mitral annular calcification. Afr Health Sci. 2019;19(1):1657–1664. doi: 10.4314/ahs.v19i1.41
  72. Gritsenko OV, Chumakova GA, Elchaninova SA, et al. Lipotoxicity damage of myocardium in obesity. CardioSomatics. 2017;8(4):36–40. (In Russ). doi: https://doi.org/10.26442/CS45386
  73. Sinitskiy MY, Ponasenko AV, Gruzdeva OV. Genetic profile and secretome of adipocytes from visceral and subcutaneous adipose tissue in patients with cardiovascular diseases. Complex Issues of Cardiovascular Diseases. 2017;(3):155–165. (In Russ). doi: 10.17802/2306-1278-2017-6-3-155-165
  74. Alnabelsi TS, Alhamshari Y, Mulki RH, et al. Relation Between Epicardial Adipose and Aortic Valve and Mitral Annular Calcium Determined by Computed Tomography in Subjects Aged ≥65 Years. Am J Cardiol. 2016;118(7):1088–1093. doi: 10.1016/j.amjcard.2016.07.012

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».